Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
10.53
-0.63 (-5.65%)
Jun 5, 2025, 10:04 AM - Market open

Bicara Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Net Income
-92.33-68-51.99-37.85
Depreciation & Amortization
0.060.060.020.01
Asset Writedown & Restructuring Costs
--0.57-
Stock-Based Compensation
9.77.41.90.81
Other Operating Activities
-0-0.0813.5-
Change in Accounts Payable
6.82.64-8.665.87
Change in Other Net Operating Assets
-12.5-16.77-0.96-0.92
Operating Cash Flow
-88.27-74.75-45.63-32.08
Capital Expenditures
-0.07-0.07-0.59-0.19
Sale of Property, Plant & Equipment
-0.06--
Investing Cash Flow
-0.07-0.01-0.59-0.19
Issuance of Common Stock
334.35334.030.150.16
Financing Cash Flow
334.35334.03272.531.7
Net Cash Flow
246.02259.27226.28-0.57
Free Cash Flow
-88.34-74.82-46.21-32.27
Free Cash Flow Per Share
-2.92-4.45-79.66-75.20
Cash Income Tax Paid
0.07--0
Levered Free Cash Flow
--53.72-32.5-
Unlevered Free Cash Flow
--53.72-32.5-
Change in Net Working Capital
-9.618.9-
Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q